. After 24-72h, to allow clearance of the photosensitiser from normal tissues, the malignant lesions are exposed to visible light, usually by laser irradiation. Tumour necrosis and regression ensue from photoradiation. It is generally agreed that cytotoxicity is mediated via formation of the highly reactive oxygen species, singlet oxygen, 102, (Weishaupt et al., 1976; Gibson et al., 1984; Parker, 1987) . Since the original promising clinical results utilised HpD, a crude preparation composed of at least seven different porphyrin species (Gibson et al., 1984; Kessel, 1986; Moan et al., 1987) , subsequent investigations were directed towards determination of the chemical structure of the 'active component' of HpD (Moan et al., 1982; Kessel and Chou, 1983; Dougherty et al., 1984) . Methods developed to purify HpD produced a porphyrin mixture enriched in the hydrophobic components, reported to be mainly dihaematoporphyrin ethers or esters (Byrne et al., 1987; Dougherty, 1987; Kessel et al., 1987) . This enriched preparation, Photofrin II, is now commercially produced for clinical and laboratory studies.
dehydrogenase. We conclude that porphyrin species contained in Photofrin II accumulate in mitochondria of tumour cells in vivo and produce maximum photosensitisation at 24-72 hours after administration to tumourbearing animals. The time course observed here with Photofrin II is similar to that seen previously with the more heterogenous haematoporphyrin derivative preparation in this in vivo-in vitro model.
Photodynamic therapy (PDT), a recently developed treatment for management of malignancies, is initiated by systemic administration of a photosensitising agent, either haematoporphyrin derivative (HpD) or the commercially available semi-purified preparation called Photofrin II, which is preferentially retained in tumour tissue (Lipson et al., 1960 ; Gomer & Dougherty, 1979) . After 24-72h, to allow clearance of the photosensitiser from normal tissues, the malignant lesions are exposed to visible light, usually by laser irradiation. Tumour necrosis and regression ensue from photoradiation. It is generally agreed that cytotoxicity is mediated via formation of the highly reactive oxygen species, singlet oxygen, 102, (Weishaupt et al., 1976; Gibson et al., 1984; Parker, 1987) . Since the original promising clinical results utilised HpD, a crude preparation composed of at least seven different porphyrin species (Gibson et al., 1984; Kessel, 1986; Moan et al., 1987) , subsequent investigations were directed towards determination of the chemical structure of the 'active component' of HpD (Moan et al., 1982; Kessel and Chou, 1983; Dougherty et al., 1984) . Methods developed to purify HpD produced a porphyrin mixture enriched in the hydrophobic components, reported to be mainly dihaematoporphyrin ethers or esters (Byrne et al., 1987; Dougherty, 1987; Kessel et al., 1987) . This enriched preparation, Photofrin II, is now commercially produced for clinical and laboratory studies.
In our earlier studies we utilised HpD as the photosensitiser (Hilf et al., , 1984 Gibson et al., 1984) . Because of the complex nature of HpD, the intracellular localisation and effects of various photosensitising components relative to time after administration could differ from the pharmacokinetics that would be observed with Photofrin II. We therefore undertook a study of Photofrin II employing the same in vivo-in vitro protocol used previously for HpD (Hilf et al., 1984) . In this protocol, the photosensitiser is injected into tumour-bearing animals, tumours are removed and subcellular organelles are prepared. These preparations are then exposed to visible light in vitro, and various biochemical endpoints are analysed, such as site-specific enzyme activities. One advantage of this protocol is that it takes into account any metabolism of the sensitiser by the tumour-bearing host. In this report, using Photofrin II as the photosensitiser, data are presented on the time-course and drug dose response of The R3230AC mammary adenocarcinoma was maintained by subcutaneous transplantation in the axillary region of 60-80g female Fischer rats, using the sterile trochar procedure described previously (Hilf et al., 1965) .
Preparation of subcellular organelles from tumours For in vitro studies, tumour-bearing rats were killed 17-24 days after implantation of the R3230AC mammary adenocarcinoma. From excised tumours, mitochondria were prepared according to methods described earlier . Briefly, R3230AC tumours were removed, weighed, placed in a dish on ice in 0.9% NaCl solution and minced with scissors. Approximately 2g of minced tumour tissue was transferred to 5ml of ice cold buffer, pH7.4, containing 0.33 M sucrose, I mM dithiothreitol, 1 mM ethyleneglycol bis (fl-aminoethyl)-N,N'-tetraacetic acid (EGTA), 0.03% bovine serum albumin and 100mM KCI. Tissues were homogenised on ice, with two 15-second bursts, with a Polytron homogeniser (Brinkmann Industries, Westbury, NY) at a setting of six. The homogenate was centrifuged at 500g for 30min at 4°C, the supernatant was removed and centrifuged at 15,000g for 30 min at 4°C. The resulting pellet was resuspended in 4 ml ice cold homogenising buffer (see above) and centrifuged at 15,000g
for 30 min at 4°C. This final pellet was resuspended in homogenisation buffer (1.5ml), which typically yielded 10-20mg mitochondrial protein per ml buffer. This mitochondrial suspension was apportioned in 0.5ml aliquots and frozen at -70°C until used. All procedures were performed in dim room light.
Treatment of mitochondrial suspensions with Photofrin II in vitro Stock solutions of Photofrin II were received frozen, thawed at room temperature, divided into 1 ml aliquots and stored at -70°C until used. All experiments were performed using dilutions of this stock preparation. Final concentrations of PIT (0.7, 3.5, were added directly to the mitochondrial suspensions prepared from tumours of untreated rats and allowed to incubate in the dark at room temperature for 10min. The suspensions were then centrifuged at 8,000g, the supernatant containing the unbound porphyrin was removed and the mitochondria were resuspended in preparation buffer before photoradiation.
Administration of Photofrin II to tumour-bearing hosts; in vivo-in vitro protocol The same in vivo-in vitro protocol employed earlier (Hilf et al., 1984) (30min, 2, 6, 18, 24, 48, 72, 120 or 168h) . Mitochondria were prepared from excised tumour tissues, the remaining portions of tumours were frozen and stored at -70°C until used for preparation of cytosols as described previously (Hilf et al., 1984 
Enzyme activity analysis
The activities of cytochrome c oxidase and succinate dehydrogenase (SDH) were analysed as previously Hilf et al., 1984 (Taussky & Shorr, 1953) . The activity of the FOFI ATPase ranged from 2.3 x 10-2 to 4.3 x 10-2pumol Pi released per min per mg protein (mean 3.0 x 10-2).
Pyruvate kinase, an enzyme located in the cytosol, was assayed using 20p1 aliquots of cytosols prepared from 10% tumour homogenates, according to methods described earlier (Hilf et al., 1965 Figure 3 . The data demonstrate that each of the four mitochondrial enzymes studied displayed a dose-and fluence-dependent inhibition of activity. From these data, a rate of enzyme inhibition was calculated (% inhibition per Jcm-2) for each dose of Photofrin II administered in vivo. The rates were obtained by regression analysis of the initial region of the inhibition curve up to 270J cm 2 total fluence. When % inhibition per J cm-2 was plotted against drug dose (mgkg-1), a linear relationship was generally obtained, with deviation from linearity occurring only at the highest drug (Hilf et al., 1984) , utilising an in vivo-in vitro protocol to investigate the effects of photosensitisation on discrete biochemical parameters. This protocol allows for metabolism of the sensitiser by the host, events that may influence equilibration of the sensitiser in neoplastic cells in vivo. After accounting for appropriate controls, a demonstration of photosensitisation by in vitro photoradiation of tumour preparations leads to the conclusion that a photosensitiser must have been present in the preparation under study. The data presented provide the temporal pattern of Photofrin TI-induced photosensitisation based on its capability to inhibit selected mitochondrial and cytosolic enzymes. These results clearly indicate that the greatest extent of light-induced inhibition of mitochondrial enzyme activity occurred between 24 and 72h after administration of Photofrin II in vivo, a result quite comparable to that observed earlier when HpD was used as the photosensitiser (Hilf et al., 1984) . The results obtained for the cytosolic enzyme pyruvate kinase, however, were different when comparing HpD and Photofrin II in this in vivo-in vitro protocol. Administration of HpD resulted in an early and dramatic inhibition of pyruvate kinase activity (30min to 24 h post-injection) when those tumour cytosols were exposed to visible light, but after 24 h pyruvate kinase activity was no longer sensitised to light by HpD. However, the results presented here using Photofrin II show that pyruvate kinase activity was unaffected throughout the time course studied. The apparent disparity is probably attributable to the different compositions of the two porphyrin preparations. HpD, prepared by the method of Lipson et al. (1960) , is a complex mixture consisting of numerous hydrophilic and hydrophobic species, estimated previously to be 75% and 25% of the total porphyrins, respectively . The more hydrophilic porphyrin species of HpD, such as the isomers of haematoporphyrin and hydroxyethylvinyldeuteroporphyrin, were probably present in sufficient levels in the cytosol soon after injection such that exposure to light caused oxidative damage to cytosolic proteins. On the other hand, Photofrin II, a mixture of porphyrins enriched in the hydrophobic species (80-90% as reported by Dougherty (1987) ), presumably dihaematoporphyrin ethers and/or esters (Berenbaum et al., 1982; Byrne et al., 1987; Dougherty, 1987; Kessel et al., 1987) , would be expected to accumulate primarily in the more hydrophobic regions, such as cell membranes. If this were the case, the lower concentration of hydrophilic components (20%) in Photofrin II would be less able to produce sufficient 102 in the cytosol to cause inhibition of pyruvate kinase, the result we observed. Alternatively, the binding of those hydrophilic components in Photofrin II may not have been sufficient to maintain a porphyrin-pyruvate kinase complex for longer periods of time in vivo, as was suggested by Freitas & Novarina (1987) for lactate dehydrogenase in HeLa cells. It should be noted that we administered 80 mg kg-1 HpD previously (Hilf et al., 1984) against 25mg kg-' Photofrin II in the present study and obtained similar patterns of inhibition of mitochondrial inner membrane enzymes. A simple calculation shows that similar amounts of hydrophobic porphyrin components were administered in both studies, approximately 20mgkg-' from each preparation.
It is of continued interest that apparent differences exist in the photosensitivities of mitochondrial enzymes subsequent to administration of Photofrin II. From studies of enzymes in vitro, such differences did not appear to be attributable to intrinsic properties, since inhibitions of semi-purified enzymes by '02 generation were comparable . Rather, we suggest that such differential sensitivity probably reflects differences in the immediate environment, their three-dimensional structure in situ and/or partitioning of hydrophobic porphyrins. Under the conditions studied here, the order of photosensitivity was cytochrome c oxidase > FOF ATPase > succinate dehydrogenase > NADH dehydrogenase. Cytochrome c oxidase, however, may possess some intrinsic properties that render it more sensitive to damage induced by porphyrin photosensitisation, such as the presence of hydrophobic regions where porphyrins may accumulate, since subunits I, II, III and VII display binding of hydrophobic reagent probes (DeMeis et al., 1988) . Also, it has been proposed that the haems and coppers may be bound to subunits I and II, although subunits V and VII have also been implicated as haem binding sites (Azzi, 1980) . Likewise it appears that the active site of mitochondrial F, ATPase, and of the Ca2 +-ATPase of the sarcoplasmic reticulum, is hydrophobic in nature, since both enzymes were inhibited by hydrophobic drugs, an effect reversed by the presence of organic solvents (DeMeis et al., 1988 (Singh et al., 1987; Moreno et al., 1987) , HpD (Berns et al., 1982) and haematoporphyrin (Salet et al., 1983) . The data obtained here demonstrate the existence of a drug-dose related response of mitochondrial photosensitisation to Photofrin II. From these data, an optimum response to illumination should occur at 24-48h after drug administration, assuming that the biochemical effects on mitochondria are important for subsequent cytotoxicity. This does not imply that other events affected by PDT, such as effects on vascularity (Fingar & Henderson, 1987; Selman et al., 1985; Star et al., 1986) , are less important in producing tumour cell necrosis in the treated lesions. However the mechanisms for vascular cell damage might also involve similar cellular sites of action. An additional consideration is the expected hydrophobic nature of the inner mitochondrial membrane, which not only should favour accumulation of hydrophobic components of Photofrin II, but could also enhance the lifetime of 102 (Parker & Stanbro, 1981) , thus increasing the potential damage.
The data presented here, along with our earlier observations (Hilf et al., 1984; Murant et al., 1987; Gibson et al., 1988) , allow us to propose a chronology of intracellular distribution of photosensitising components of Photofrin II in a neoplasm in vivo (Table I) . At 2h after administration of Photofrin II, porphyrins have accumulated in the plasma membrane and have entered the outer membrane of mitochondria. This is deduced from the photoradiation-induced inhibition of Na+K+ATPase (plasma membrane) and monoamine oxidase (outer mitochondrial membrane) at 2h post-treatment. At this early time after Photofrin II administration, as well as throughout the timecourse studied, neither the cytosolic enzyme pyruvate kinase nor adenylate kinase, located in the intramembrane space of mitochondria, were inhibitable by photoradiation in vitro. Although photoradiation-induced inhibition of the inner mitochondrial membrane enzymes, succinate dehydrogenase, cytochrome c oxidase and FOFI ATPase, was seen by 2h post-treatment, the degree of inhibition of these enzymes progressively increased to reach a maximum by 24h ( Figure  2 and Table I ). At the 24 h time point, only the inner mitochondrial membrane enzymes and the plasma membrane enzyme Na+K+ATPase demonstrated a significant inhibition. This photosensitisation persisted for 72 h, after which less inhibition resulted from illumination. Thus, if the effects observed on enzyme activity accurately reflect the location of photosensitisers, the active components in Gibson et al. (1988) and for monoamine oxidase and adenylate kinase are from Murant et al. (1987) .
Photofrin II demonstrate a time-dependent intracellular distribution that results in their retention in the plasma membrane and the inner mitochondrial membrane following in vivo administration. Bohmer & Morstyn (1985) reported that cellular uptake of HpD in vitro occurred in two phases; the first was rapid (seconds) and the porphyrin components were readily removed by washing with serum-containing medium, whereas the second phase took hours and the porphyrins incorporated into the cytosol and intracellular organelles could not be removed by serum-containing medium. A somewhat similar pattern was observed by Kessel (1986) with L1210 cells in vitro by comparing events after 30 min, 4 and 18 h incubations with HpD. Based on membrane transport, thymidine incorporation and cellular ATP levels, the longer incubation times resulted in photosensitised damage at intracellular membrane sites compared to the plasma membrane damage observed at the shorter incubation times. Earlier, Moan et al. (1983) observed that, in NHIK 3025 cells in culture, incubation with HpD for 1 versus 18 h resulted in a change of photosensitisable damage from the plasma membrane to intracellular sites as incubation times increased. The differences in the time course seen in our present study and those of Moan et al. or Kessel are probably attributable to differences in the exposure of tumour cells in vivo to circulating levels of porphyrins, extending the period of time that these cells and their organelles remain in the presence of the components of either HpD or Photofrin II.
In conclusion, administration of Photofrin II to tumourbearing rats and study of the subsequent photosensitisation of selected enzymes, i.e. the in vivo-in vitro protocol, results in mitochondrial enzyme inhibitions that are dependent on the time interval between administration of the drug and exposure of the mitochondria to visible light, on the dose of Photofrin II administered in vivo and on the total fluence used to photoradiate the samples. Although the data presented here are in general agreement with data we previously obtained using HpD as the photosensitiser, clinical use of Photofrin II will require establishing a protocol to achieve maximum efficacy.
